Is REVVITY, INC. (RVTY) Halal?

NYSE Healthcare United States $9.4B
✗ NOT HALAL
Confidence: 90/100
REVVITY, INC. (RVTY) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 32.8% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. REVVITY, INC. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 32.8%
/ 30%
8.9%
/ 30%
7.2%
/ 30%
1.09%
/ 5%
✗ NOT HALAL
DJIM 32.8%
/ 33%
8.9%
/ 33%
7.2%
/ 33%
1.09%
/ 5%
✓ HALAL
MSCI 27.9%
/ 33%
7.6%
/ 33%
6.1%
/ 33%
1.09%
/ 5%
✓ HALAL
S&P 32.8%
/ 33%
8.9%
/ 33%
7.2%
/ 33%
1.09%
/ 5%
✓ HALAL
FTSE 27.9%
/ 33%
7.6%
/ 33%
6.1%
/ 50%
1.09%
/ 5%
✓ HALAL

Financial Highlights

P/E Ratio
40.7
Forward: 14.0
EPS
$2.06
Dividend Yield
33.0%
Payout: 13.6%
P/B Ratio
1.3
EV/EBITDA
14.1
EV: $11.9B
Revenue
$2.9B
Growth: 5.9%
Beta
1.1
Average volatility
Current Ratio
1.7

Profitability

Gross Margin 54.8%
Operating Margin 20.1%
Net Margin 8.4%
Return on Equity (ROE) 3.2%
Return on Assets (ROA) 2.2%

Cash Flow & Balance Sheet

Operating Cash Flow$583M
Free Cash Flow$509M
Total Debt$3.4B
Debt-to-Equity46.9
Current Ratio1.7
Total Assets$12.2B

Price & Trading

Last Close$87.12
50-Day MA$98.58
200-Day MA$95.36
Avg Volume1.3M
Beta1.1
52-Week Range
$81.36
$118.30

About REVVITY, INC. (RVTY)

CEO
Dr. Prahlad R. Singh Ph.D.
Employees
11,000
Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Exchange
NYSE
Market Cap
$9.4B
Currency
USD

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is REVVITY, INC. (RVTY) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), REVVITY, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is REVVITY, INC.'s debt ratio?

REVVITY, INC.'s debt ratio is 32.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 27.9%.

What are REVVITY, INC.'s key financial metrics?

REVVITY, INC. has a market capitalization of $9.4B, trailing P/E ratio of 40.7, and revenue of $2.9B. The company maintains a gross margin of 54.8% and a net margin of 8.4%. Return on equity stands at 3.2%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.